Benzinga | Nov 4, 2021 09:26AM EDT

Sangamo Therapeutics Q3 EPS $(0.33) Beats $(0.34) Estimate, Sales $28.56M Beat $25.19M Estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.34) by 2.94 percent. This is a 3200 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $28.56 million which beat the analyst consensus estimate of $25.19 million by 13.39 percent. This is a 50.55 percent decrease over sales of $57.76 million the same period last year.